148 related articles for article (PubMed ID: 25578869)
1. A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck.
Patil VM; Noronha V; Joshi A; Muddu VK; Dhumal S; Bhosale B; Arya S; Juvekar S; Banavali S; D'Cruz A; Bhattacharjee A; Prabhash K
Oral Oncol; 2015 Mar; 51(3):279-86. PubMed ID: 25578869
[TBL] [Abstract][Full Text] [Related]
2. Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part).
Vermorken JB; Peyrade F; Krauss J; Mesía R; Remenar E; Gauler TC; Keilholz U; Delord JP; Schafhausen P; Erfán J; Brümmendorf TH; Iglesias L; Bethe U; Hicking C; Clement PM
Ann Oncol; 2014 Mar; 25(3):682-688. PubMed ID: 24567516
[TBL] [Abstract][Full Text] [Related]
3. Repurposing pantoprazole in combination with systemic therapy in advanced head and neck squamous cell carcinoma: a phase I/II randomized study.
Noronha V; Patil V; Menon N; Kalra D; Singh A; Shah M; Goud S; Jobanputra K; Nawale K; Shah S; Chowdhury OR; Mathrudev V; Jogdhankar S; Singh MY; Singh A; Adak S; Sandesh M; Arunkumar R; Kumar S; Mahajan A; Prabhash K
Med Oncol; 2023 Dec; 41(1):26. PubMed ID: 38129716
[TBL] [Abstract][Full Text] [Related]
4. An audit of the results of a triplet metronomic chemotherapy regimen incorporating a tyrosine kinase inhibitor in recurrent/metastatic head and neck cancers patients.
Patil VM; Chakraborty S; Jithin TK; Sajith Babu TP; Babu S; Kumar S; Biji MS; Bhattacharjee A; Balasubramanian S
South Asian J Cancer; 2016; 5(2):48-51. PubMed ID: 27275445
[TBL] [Abstract][Full Text] [Related]
5. Triple combination of palliative oral metronomic chemotherapy in recurrent and metastatic epithelial ovarian cancer: A retrospective study.
Harsh KK; Jakhar SL; Maheshwari G; Nirban R; Kumari P; Beniwal SK; Sharma N; Kumar HS
Indian J Cancer; 2023; 60(2):167-172. PubMed ID: 37530237
[TBL] [Abstract][Full Text] [Related]
6. Oral metronomic therapy as a resource-adaptive palliative strategy for recurrent/metastatic head and neck squamous cell cancers.
Kaul P; Garg PK
Oral Oncol; 2023 Nov; 146():106576. PubMed ID: 37742471
[No Abstract] [Full Text] [Related]
7. Combined Metronomic Chemo-immunotherapy (CMCI) in Head and Neck Cancers-An Experience from a Developing Country.
Madabhavi I; Sarkar M; Kumar V; Sagar R
Indian J Surg Oncol; 2024 Jun; 15(2):321-331. PubMed ID: 38741631
[TBL] [Abstract][Full Text] [Related]
8. Metronomic Chemotherapy in Oral Cancer: A Review.
Sethuraman S; Ramalingam K
Cureus; 2023 Dec; 15(12):e49825. PubMed ID: 38169679
[TBL] [Abstract][Full Text] [Related]
9. Low-Dose Immunotherapy Plus Triple Metronomic Chemotherapy for Head and Neck Cancer.
Mo DC; Huang JF; Luo PH
J Clin Oncol; 2023 Mar; 41(9):1790. PubMed ID: 36669141
[No Abstract] [Full Text] [Related]
10. Metronomic Chemotherapy in Elderly Patients.
Bandini A; Calabrò PF; Banchi M; Orlandi P; Bocci G
Curr Oncol Rep; 2024 Apr; 26(4):359-376. PubMed ID: 38448722
[TBL] [Abstract][Full Text] [Related]
11. A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma.
Gilbert J; Schell MJ; Zhao X; Murphy B; Tanvetyanon T; Leon ME; Neil Hayes D; Haigentz M; Saba N; Nieva J; Bishop J; Sidransky D; Ravi R; Bedi A; Chung CH
Oral Oncol; 2015 Apr; 51(4):376-82. PubMed ID: 25593015
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study.
Petrioli R; Roviello G; Fiaschi AI; Laera L; Marrelli D; Roviello F; Francini E
Cancer Chemother Pharmacol; 2015 Apr; 75(4):683-90. PubMed ID: 25618415
[TBL] [Abstract][Full Text] [Related]
13. Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer.
Wang J; Xu R; Li J; Bai Y; Liu T; Jiao S; Dai G; Xu J; Liu Y; Fan N; Shu Y; Ba Y; Ma D; Qin S; Zheng L; Chen W; Shen L
Gastric Cancer; 2016 Jan; 19(1):234-44. PubMed ID: 25604851
[TBL] [Abstract][Full Text] [Related]
14. Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom.
Cao X; Ejzykowicz F; Ramey DR; Sajjan S; Ambegaonkar BM; Mavros P; Tunceli K
Clin Ther; 2015 Apr; 37(4):804-15. PubMed ID: 25626487
[TBL] [Abstract][Full Text] [Related]
15. Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study.
Lauria G; Dalla Bella E; Antonini G; Borghero G; Capasso M; Caponnetto C; Chiò A; Corbo M; Eleopra R; Fazio R; Filosto M; Giannini F; Granieri E; La Bella V; Logroscino G; Mandrioli J; Mazzini L; Monsurrò MR; Mora G; Pietrini V; Quatrale R; Rizzi R; Salvi F; Siciliano G; Sorarù G; Volanti P; Tramacere I; Filippini G;
J Neurol Neurosurg Psychiatry; 2015 Aug; 86(8):879-86. PubMed ID: 25595151
[TBL] [Abstract][Full Text] [Related]
16. Thrombopoiesis-stimulating agents and myelodysplastic syndromes.
Brierley CK; Steensma DP
Br J Haematol; 2015 May; 169(3):309-23. PubMed ID: 25659186
[TBL] [Abstract][Full Text] [Related]
17. Trimethoprim-sulfamethoxazole and risk of sudden death among patients taking spironolactone.
Antoniou T; Hollands S; Macdonald EM; Gomes T; Mamdani MM; Juurlink DN;
CMAJ; 2015 Mar; 187(4):E138-E143. PubMed ID: 25646289
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant carboplatin, paclitaxel, and vaginal cuff brachytherapy for stage III endometrial cancer: analysis of outcomes and patterns of recurrence based on pathologic characteristics.
Young MR; Higgins SA; Ratner E; Yu JB; Mani S; Silasi DA; Azodi M; Rutherford T; Schwartz PE; Damast S
Int J Gynecol Cancer; 2015 Mar; 25(3):431-9. PubMed ID: 25621409
[TBL] [Abstract][Full Text] [Related]
19. Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial.
Mesía R; Henke M; Fortin A; Minn H; Yunes Ancona AC; Cmelak A; Markowitz AB; Hotte SJ; Singh S; Chan AT; Merlano MC; Skladowski K; Zhang A; Oliner KS; VanderWalde A; Giralt J
Lancet Oncol; 2015 Feb; 16(2):208-20. PubMed ID: 25596660
[TBL] [Abstract][Full Text] [Related]
20. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial.
Giralt J; Trigo J; Nuyts S; Ozsahin M; Skladowski K; Hatoum G; Daisne JF; Yunes Ancona AC; Cmelak A; Mesía R; Zhang A; Oliner KS; VanderWalde A
Lancet Oncol; 2015 Feb; 16(2):221-32. PubMed ID: 25596659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
